What is "idraparinux"

Idraparinux sodium is an anticoagulant medication in development by Sanofi-Aventis.

It has a similar chemical structure and the same method of action as fondaparinux, but with an elimination half-life about five to six times longer (an increase from fondaparinux's 17 hours to approximately 80 hours), which means that the drug should only need to be injected once a week.

Sanofi discontinued the development of idraparinux sodium.